Yong Hyun Jeon1, Yun Choi2, Jaetae Lee3, Chul Woo Kim4, June-Key Chung5. 1. Department of Nuclear Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea ; Tumor Immunity Medical Research Center, Seoul National University College of Medicine, Seoul, Korea ; Laboratory of Molecular Imaging and Therapy of Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea ; Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. 2. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea ; Tumor Immunity Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. 3. Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. 4. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea ; Tumor Immunity Medical Research Center, Seoul National University College of Medicine, Seoul, Korea ; Department of Pathology, Tumor Immunity Medical Research Center and Cancer Research Institute, Seoul National University, College of Medicine, 28 Yongon-Dong, Jongno-Gu, Seoul, 110-799 Korea. 5. Department of Nuclear Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea ; Tumor Immunity Medical Research Center, Seoul National University College of Medicine, Seoul, Korea ; Laboratory of Molecular Imaging and Therapy of Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Abstract
PURPOSE: The authors evaluated whether the cytotoxicity of CD8+CTLs generated by combined hMUC1 vaccination and hNIS radioiodine gene therapy was enhanced in the presence of CpG in an established tumor model. METHODS: CMNF cells (CT26 cells expressing hMUC1, hNIS and Firefly luciferase) were transplanted into BALB/c mice. Four and 10 days later, tumor-bearing mice were immunized intramuscularly with pcDNA3.1 or pcDNA-hMUC1 or pcDNA-hMUC1+CpG, and subsequently administered PBS or (131)I [five groups (seven mice/group): referred to as the pcDNA3.1+PBS, phMUC1+PBS, pcDNA3.1+(131)I, phMUC1+(131)I, and phMUC1+(131)I+CpG groups]. The number of CD8+IFNr+ T cells of splenocytes as well as the number of CD8+IFNr+ T cells of splenocytes re-stimulated with CD11c+ cells was determined using FACS analysis. The activities of cytotoxic T cells (CTLs) from splenocytes were investigated. RESULTS: Marked tumor growth inhibition was observed in the phMUC1+(131)I and phMUC1+(131)I+CpG groups, but not in the other three single therapy groups. Particularly the number of CD8+IFN-γ+ T cells of splenocytes was more increased in the phMUC1+(131)I+CpG group than in the phMUC1+(131)I group. The number of CD8+IFN-γ+ T cells of splenocytes stimulated with CD11c+ cells was the most enhanced in the phMUC1+(131)I+CpG group among the five groups. Concurrently, the activities of hMUC1-associated CTLs obtained from splenocytes in the phMUC1+(131)I+CpG group were significantly greater than in the other four groups (pcDNA+PBS, phMUC1+PBS, pcDNA+(131)I, phMUC1+(131)I, and phMUC1+(131)I+CpG, 16 ± 2%, 20 ± 1%, 30 ± 2%, 60 ± 2%, and 87 ± 2%, respectively, P < 0.01). CONCLUSION: Our data suggest that adjuvant CpG ODNs can increase the killing activities of CTLs generated by combined hMUC1 DNA vaccination and hNIS radioiodine gene therapy.
PURPOSE: The authors evaluated whether the cytotoxicity of CD8+CTLs generated by combined hMUC1 vaccination and hNIS radioiodine gene therapy was enhanced in the presence of CpG in an established tumor model. METHODS: CMNF cells (CT26 cells expressing hMUC1, hNIS and Firefly luciferase) were transplanted into BALB/c mice. Four and 10 days later, tumor-bearing mice were immunized intramuscularly with pcDNA3.1 or pcDNA-hMUC1 or pcDNA-hMUC1+CpG, and subsequently administered PBS or (131)I [five groups (seven mice/group): referred to as the pcDNA3.1+PBS, phMUC1+PBS, pcDNA3.1+(131)I, phMUC1+(131)I, and phMUC1+(131)I+CpG groups]. The number of CD8+IFNr+ T cells of splenocytes as well as the number of CD8+IFNr+ T cells of splenocytes re-stimulated with CD11c+ cells was determined using FACS analysis. The activities of cytotoxic T cells (CTLs) from splenocytes were investigated. RESULTS: Marked tumor growth inhibition was observed in the phMUC1+(131)I and phMUC1+(131)I+CpG groups, but not in the other three single therapy groups. Particularly the number of CD8+IFN-γ+ T cells of splenocytes was more increased in the phMUC1+(131)I+CpG group than in the phMUC1+(131)I group. The number of CD8+IFN-γ+ T cells of splenocytes stimulated with CD11c+ cells was the most enhanced in the phMUC1+(131)I+CpG group among the five groups. Concurrently, the activities of hMUC1-associated CTLs obtained from splenocytes in the phMUC1+(131)I+CpG group were significantly greater than in the other four groups (pcDNA+PBS, phMUC1+PBS, pcDNA+(131)I, phMUC1+(131)I, and phMUC1+(131)I+CpG, 16 ± 2%, 20 ± 1%, 30 ± 2%, 60 ± 2%, and 87 ± 2%, respectively, P < 0.01). CONCLUSION: Our data suggest that adjuvant CpG ODNs can increase the killing activities of CTLs generated by combined hMUC1 DNA vaccination and hNIS radioiodine gene therapy.
Authors: James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531
Authors: Kathryn A Mason; Hisanori Ariga; Robert Neal; David Valdecanas; Nancy Hunter; Arthur M Krieg; John K Whisnant; Luka Milas Journal: Clin Cancer Res Date: 2005-01-01 Impact factor: 12.531
Authors: Nathalie Chaput; Nöel E C Schartz; Fabrice André; Julien Taïeb; Sophie Novault; Pierre Bonnaventure; Nathalie Aubert; Jacky Bernard; François Lemonnier; Miriam Merad; Gosse Adema; Malcolm Adams; Maria Ferrantini; Antoine F Carpentier; Bernard Escudier; Thomas Tursz; Eric Angevin; Laurence Zitvogel Journal: J Immunol Date: 2004-02-15 Impact factor: 5.422
Authors: Kwang Il Kim; Yong Jin Lee; Tae Sup Lee; Inho Song; Gi Jeong Cheon; Sang Moo Lim; June-Key Chung; Joo Hyun Kang Journal: Nucl Med Mol Imaging Date: 2012-09-06
Authors: Ho Won Lee; Seung Yun Yoon; Thoudam Debraj Singh; Yoon Ju Choi; Hong Je Lee; Ji Young Park; Shin Young Jeong; Sang-Woo Lee; Jeoung-Hee Ha; Byeong-Cheol Ahn; Yong Hyun Jeon; Jaetae Lee Journal: Sci Rep Date: 2015-05-14 Impact factor: 4.379